skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: Journals@OVID remover tipo de recurso: Outros remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Local NET Burden is Associated With Biomarkers of Thrombosis and Cardiac Damage in Left Atrial Cardiopathy
Local NET Burden is Associated With Biomarkers of Thrombosis and Cardiac Damage in Left Atrial Cardiopathy
Material Type:
Outros 		Adicionar ao Meu Espaço

Local NET Burden is Associated With Biomarkers of Thrombosis and Cardiac Damage in Left Atrial Cardiopathy

Martinod, Kimberly ; Claessen, Annika ; Martens, Caroline ; Krauel, Krystin ; Pereira Velàsquez, Leydi Carolina ; Witsch, Thilo

Circulation, 2021, Vol.144 (Suppl_1)

American Heart Association

Texto completo disponível

Citações Citado por
2
Thromboinflammatory profiling in atrial cardiopathy
Thromboinflammatory profiling in atrial cardiopathy
Material Type:
Outros 		Adicionar ao Meu Espaço

Thromboinflammatory profiling in atrial cardiopathy

Claessen, Annika ; Krauel, Krystin ; Velásquez Pereira, Leydi Carolina ; Martinod, Kimberly ; Witsch, Thilo

EUROPEAN HEART JOURNAL, 2021, Vol.42, p.3277-3277

OXFORD UNIV PRESS

Texto completo disponível

Citações Citado por
3
Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study
Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study
Material Type:
Outros 		Adicionar ao Meu Espaço

Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study

Cavalli, F ; Jin, J ; Pylypenko, H ; Verhoef, G ; Siritanaratkul, N ; Drach, J ; Raderer, M ; Mayer, J ; Pereira, J ; Tumyan, G ; Okamoto, R ; Nakahara, S ; Hu, P ; Appiani, C ; Nemat, S ; Robak, T

ANNALS OF ONCOLOGY, 2018, Vol.29, p.359-359

OXFORD UNIV PRESS

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Data de Publicação 

De até
Refinar

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.